Agenus enters research agreement with Memorial Sloan-Kettering Cancers Center Agenus Inc.

The collaboration will check Agenus’ cancers vaccine in conjunction with antibodies that are intended to target particular markers on tumor cells, such as for example CTLA-4 and PDL-1. This band of antibodies represents a new class of immunotherapeutic agents that are believed to have complementary mechanisms of action with cancer vaccines. The research will be performed in the laboratory of Jedd D. Wolchok, M.D., Ph.D., a leader in neuro-scientific cancer immunotherapy. Dr. Wolchok acts as the Associate Director of the Ludwig Middle for Cancers Immunotherapy at MSKCC as well as Director of Immunotherapy Clinical Trials.Results Study Participants A total of 4733 participants were signed up for the ACCORD BP trial. Of these, 2362 were randomly designated to intensive blood-pressure control and 2371 were assigned to regular therapy. Baseline characteristics were generally equivalent between the two groups . The mean age of the participants was 62.24 months; 47.7 percent were women and 33.7 percent had coronary disease at baseline. The mean diastolic and systolic blood pressures of the participants at baseline were 139.2 mm Hg and 76.0 mm Hg, respectively. At the end of the trial , vital status was known for 95.1 percent of the randomly assigned participants.